Wei Dai

University of Hong Kong

Dr. Wei Dai attended China Medical University for her bachelor’s degree and obtained her MSc. in Bioinformatics from the University of Manchester in UK. In 2011, she finished her PhD in Cancer Bioinformatics in the Department of Surgery and Cancer, Faculty of Medicine in Imperial College London in UK. She was awarded British Association of Cancer Research (BACR) Gordon Hamilton-Fairley Young Investigator Award for her PhD study on methylation prognostic biomarkers for epithelial ovarian cancer. She joined the Department of Clinical Oncology at the University of Hong Kong as Postdoctoral Research Fellow in 2013 and became Research Assistant Professor in 2016. Now she is working as Assistant Professor in the Department of Clinical Oncology with research focus on cancer genomics, tumour immunology, and the molecular mechanisms driving metastasis in virus-associated cancers. In 2024, she obtained Guangdong Natural Science Award for Nasopharyngeal Carcinoma (NPC) Precision Treatment and Novel Immune Target Innovation: Breakthrough Research on New Technologies and Mechanisms. As a recognised researcher in the field of cancer multi-omics for NPC, Dr. Dai serves as a peer reviewer for journals such as Nature Genetics, Nature Communications, Advanced Sciences, Gut, and Oncogene etc.

Shyam Prabhakar

A*STAR, Singapore

Shyam Prabhakar obtained a B.Tech in Electronics Engineering from IIT-Madras and a PhD in Applied Physics from Stanford University. He received the 2001 American Physical Society PhD thesis award for Beam Physics and received postdoctoral training at Stanford and Lawrence Berkeley National Laboratory. His lab at the Genome Institute of Singapore uses spatial & single-cell assays and novel algorithms to tackle common diseases. Major initiatives include leading the Asian Immune Diversity Atlas (AIDA) consortium and the TISHUMAP spatial omics programme for target discovery. He serves on the Human Cell Atlas (HCA) Executive Committee and co-leads the HCA Genetic Diversity Network and Data Ecosystem Oversight group.

Quentin Gouil

Olivia Newton-John Cancer Research Institute

Dr Gouil is an NHMRC Emerging Leadership fellow and lab head at the Olivia Newton-John Cancer Research Institute in Heidelberg, Australia. 

Dr Gouil obtained a PhD in Plant Epigenetics from the University of Cambridge, UK, where he studied transgenerational epigenetic inheritance and the mechanisms of DNA methylation. His postdoctoral work at La Trobe University revealed how the genome awakens from dormancy during seed germination. Dr Gouil then joined the Walter and Eliza Hall Institute to leverage long-read sequencing to study mammalian epigenetics in health and disease. 

At the Olivia Newton-John Cancer Research Institute, Dr Gouil’s Health and Epigenomics Across Life (HEAL) lab combines computational and molecular approaches to reveal how the genome functions and bring about genomic-informed personalised medicine.

Roxane Legaie

Children’s Cancer Institute

Roxane Legaie is the Head of Clinical Informatics for the ZERO program at the Children’s Cancer Institute, joining the team in 2026 to support the data-driven future of paediatric precision medicine.

With nearly two decades of experience across both academic and clinical bioinformatics, she is an expert in the development, validation, and NATA accreditation of high-stakes clinical genomics pipelines.

Prior to her current role, Roxane spent eight years at the Peter MacCallum Cancer Centre as the Clinical Bioinformatics Team Leader, where she coordinated the informatics requirements for the Molecular Pathology department, ensuring the establishment of a fully accredited genomics laboratory.

An approachable leader and strategic advisor, Roxane specialises in coordinating diverse teams of bioinformaticians, pathologists, and clinicians. She is dedicated to ensuring that complex bioinformatics solutions translate into seamless, high-quality diagnostic tools that empower clinicians and improve outcomes for cancer patients and their families.